Macitentan

4 trials 1 recruiting CCardiology Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

2 Sponsors

16 Countries

Phase III

Phase II

Phase III: 3 Phase II: 1

Indications tested

Pulmonary arterial hypertension 2 Pulmonary hypertension 1

Sponsors using this IMP

Actelion Pharmaceuticals Ltd. 3 Assistance Publique Hopitaux De Paris 1

All trials

4 total

A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent … Recruiting

2023-506791-27-00 Phase III 3 countries Actelion Pharmaceuticals Ltd.
A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended

2024-515669-32-00 Phase III 16 countries Actelion Pharmaceuticals Ltd.
IMPACT-CTEPH Ended

2024-513672-17-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A multicenter, open-label, randomized study with single-arm extension period to assess the pharmacokinetics, safety and efficacy of macitent… Ended

2023-509845-10-00 Phase III 4 countries Actelion Pharmaceuticals Ltd.

Showing 1–4 of 4 trials

← All drugs A–Z